Zobrazeno 1 - 10
of 140
pro vyhledávání: '"adverse event (AE)"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundPralsetinib, a selective oral inhibitor of rearranged during transfection (RET) fusion proteins and oncogenic RET mutants, has shown significant efficacy in treating RET fusion-positive non-small cell lung cancer and thyroid cancer. However
Externí odkaz:
https://doaj.org/article/b370a1dfd9c8400b88880881b9190b94
Publikováno v:
Frontiers in Surgery, Vol 11 (2024)
IntroductionRadical nephroureterectomy with concurrent bladder cuff excision (RNUBCE) is the gold standard surgical approach for high-risk primary upper tract urothelial carcinoma (UTUC). Given the notably high incidence of bladder tumor recurrence f
Externí odkaz:
https://doaj.org/article/d0ab95c0bb5e4205b66ef15bcbdd818f
Autor:
Sarya Swed, Hidar Alibrahim, Haidara Bohsas, Ahmed R. N. Ibrahim, Abdelmonem Siddiq, Nagham Jawish, Mark Hasib Makhoul, Maram Abdulmajid Mahmoud Alrezej, Fouad Hasib Makhoul, Bisher Sawaf, Wael Hafez, Sarah Makram Elsayed, Rami Soliman, Engy A. Wahsh
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: Proton pump inhibitors (PPIs) are commonly used to treat acid-related disorders. Their appropriate use depends on the correct indications from the clinician. Owing to the high incidence of use and misuse, PPIs have been identified as an
Externí odkaz:
https://doaj.org/article/19c1580f4bd846e88e3c34e553c9ee45
Autor:
Thomas Salaets, Thierry Lacaze-Masmonteil, Isamu Hokuto, Cheri Gauldin, Amjad Taha, Anne Smits, Liesbeth Thewissen, Ilse Van Horebeek, Armuchou Shoraisham, Khorshid Mohammad, Manami Suzuki, Shiori Komachi, Kurt Michels, Mark A. Turner, Karel Allegaert, Tamorah Lewis
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: To ensure the quality of clinical trial safety data, universal data standards are required. In 2019 the International Neonatal Consortium (INC) published a neonatal adverse event severity scale (NAESS) to standardize the reporting of ad
Externí odkaz:
https://doaj.org/article/970dfc289e2741f89ddda1248b561151
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: existing research on children consists primarily of phase I/II clinical trials for VEGFR-TKI. System reports of safety on the use of VEGFR-TKI in pediatrics are lacking.Aim: to investigate the safety profiles of VEGFR-TKI in pediatrics
Externí odkaz:
https://doaj.org/article/f11a07545a024c97bc9aa4a2d091e169
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide and often diagnosed at advanced stages with poor prognosis. Combination of radiotherapy and immunotherapy seems to be a promising approach for treating ESCC. This comprehensiv
Externí odkaz:
https://doaj.org/article/34b3c70140bf4415a67050096eaa3890
Autor:
Mimi M. Kim, Isabella Steffensen, Red Thaddeus D. Miguel, Tanja Babic, Aubrey D. Johnson, Julien Carlone, Ryan Potts, Christopher S. Junker
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
Associations between cigarette smoking and increased risk of cardiovascular disease are well established. However, it is unclear whether the association is mediated by exposure to nicotine and/or to other constituents in cigarette smoke. The objectiv
Externí odkaz:
https://doaj.org/article/866e82d8810f4bae95620d42062dd47a
Autor:
Keywan Mortezaee, Jamal Majidpoor
Publikováno v:
Heliyon, Vol 9, Iss 3, Pp e14566- (2023)
Background: This review discusses the impact of mono or combination therapy of immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC) patients, comparing clinical outcomes and safety. Cancer subtype, tumor mutational burden (
Externí odkaz:
https://doaj.org/article/28798add8c444ea992cbdfdd2303bc1b
Autor:
Ruijie Li, Fuping Chen, Xuanxuan He, Yuqing Feng, Qiaoqiao Pei, Dongke Wang, Xinghuang Liu, Jinsong Liu, Xiaohua Hou, Tao Bai
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
ObjectiveTo estimate the magnitude of the nocebo response and explore its influencing factors in irritable bowel syndrome (IBS).MethodsThe PubMed, Embase, and Cochrane Library databases were searched up to March 2021. We performed a random effects me
Externí odkaz:
https://doaj.org/article/f8eae5c79be94d69853b9f915a61ea50
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Aim of the reviewTo assess the risk of hypovolemia for sodium–glucose cotransporter-2 (SGLT2) inhibitors treatment.MethodA systematic literature retrieval was performed in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), We
Externí odkaz:
https://doaj.org/article/f2f03c5f63b34bd68f956c9919e609e9